Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as bryostatin 1, work in different ways to stop
cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as
rituximab can locate cancer cells and either kill them or deliver cancer-killing substances
to them without harming normal cells. Bryostatin 1 may help rituximab kill more cancer cells
by making them more sensitive to the drug.
PURPOSE: This phase II trial is studying how well giving bryostatin 1 together with rituximab
works in treating patients with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia
that has not responded to previous treatment with rituximab.